The Catholic University of Korea Street. Vincent Hospital
Welcome,         Profile    Billing    Logout  
 14 Trials 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Yun Jung
TARGET, NCT06622603: The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More

Not yet recruiting
4
59
RoW
Febuxostat, Usoric® Tab 40mg
Seoul National University Hospital, Gachon University Gil Medical Center, SMG-SNU Boramae Medical Center, Chungnam National University Hospital, Seoul National University Bundang Hospital, Eulji University Hospital, Ajou University Medical Center
Gout, Uric Acid
04/26
10/26
ATTENTION, NCT03753074: Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines

Active, not recruiting
4
780
RoW
Tenofovir Alafenamide, Vemlidy
Young-Suk Lim, Samsung Medical Center, Kyunghee University Medical Center, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul National University Hospital, Ulsan University Hospital, Konkuk University Medical Center, Kyungpook National University Hospital, Korea University Guro Hospital, Seoul St. Mary's Hospital, Kaohsiung Medical University, Chang Gung Memorial Hospital, E-DA Hospital, Taitung Mackay Memorial Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital, Chiayi Christian Hospital, St. Martin De Porress Hospital, Dalin Tzu Chi General Hospital, Taichung Veterans General Hospital, China Medical University Hospital, Seoul National University Bundang Hospital
Chronic Hepatitis b
12/31
12/31
AYP-101-301, NCT06256445: Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

Recruiting
3
252
RoW
Polyene Phosphatidylcholine, AYP-101, Matching placebo of AYP-101, Placebo
AMIpharm Co., Ltd.
Healthy
08/24
08/25
KEYNOTE-C98, NCT05405595: ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Recruiting
1/2
131
US, RoW
ADG126, Pembrolizumab (KEYTRUDA®)
Adagene Inc, Merck Sharp & Dohme LLC
Advanced/Metastatic Solid Tumors
03/25
09/25
NCT05776680: The Effects of Multi-Psycho-Oncology Care Courses

Recruiting
N/A
280
RoW
Psychological support
National Taiwan University Hospital
Cancer, Psychological, Oncology, Empathy
10/23
12/24
NCT05788809: Communication Skill and Related Factors Among Oncology Nurses

Completed
N/A
527
RoW
National Taiwan University Hospital
Oncology, Nurse, Communication
12/23
01/24
NCT06414564: Effects of AHCL Insulin Pump on Glycemic Control and Psychosocial Outcomes in Pediatric Patients With Type 1 Diabetes

Recruiting
N/A
30
RoW
Medtronic 780G insulin pump
Seoul National University Hospital, Medtronic
Type 1 Diabetes
06/25
12/25
NCT05977504: The Effectiveness of "Multi-Psychological Empowerment" Courses

Not yet recruiting
N/A
100
RoW
Multi-Psychological Empowerment Courses
National Taiwan University Hospital
Cancer, Oncology, Psychological, Self Efficacy, Communication
04/24
07/24
Lee, Ki Hwa
REMBRANDT, NCT04700436: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

Recruiting
4
240
RoW
Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg), Suvast tablet 10 mg (Rosuvastatin 10 mg)
Seoul National University Hospital, Gangnam Severance Hospital
Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias
05/21
11/21
PEARLY, NCT02441933: Carboplatin in EARLY Triple Negative Breast Cancer Trial ( Trial)

Active, not recruiting
3
878
RoW
taxane plus carboplatin, Taxane
Yonsei University
Breast Cancer
06/25
06/25
NCT05219617 / 2022-001256-42: Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Recruiting
3
252
Europe, US, RoW
Carisbamate
SK Life Science, Inc., SK Life Science, Inc
Seizures, Lennox Gastaut Syndrome
06/25
06/26
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
02/24
12/25
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hourglass Nov 2024 - Dec 2024 : Initial data from trial in combination with Libtayo for advanced NSCLC
Recruiting
2/3
850
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals
Advanced Non-Small Cell Lung Cancer
03/30
02/32
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
KCSG AL19-17, NCT04647838: Tepotinib in Solid Tumors Harboring MET Alterations

Recruiting
2
100
RoW
Tepotinib, MSC2156119J, EMD 1214063
Chungbuk National University Hospital, Merck KGaA, Darmstadt, Germany
Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification
02/23
08/24
NCT04680026 / 2022-001021-74: A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Active, not recruiting
2
150
Canada, US, RoW
HBI-3000, sulcardine sulfate, Placebo
HUYABIO International, LLC., HUYABIO International, LLC
Atrial Fibrillation
06/25
06/25
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Withdrawn
2
115
RoW
EP0057, Olaparib tablets
Ellipses Pharma
Gastric Cancer, Small-cell Lung Cancer
08/24
12/24
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Recruiting
2
40
US, RoW
ABN401
Abion Inc
Advanced Solid Tumors
04/25
08/25
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
NCT05076838: Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy

Active, not recruiting
1/2
30
US
Diazepam Nasal Spray [Valtoco]
Neurelis, Inc.
Epilepsy
08/23
10/24
TRX-221-001, NCT06186076: A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Recruiting
1/2
115
RoW
TRX-221
Therapex Co., Ltd
Carcinoma, Non-Small-Cell Lung, EGFR Mutant Advanced Non-Small Cell Lung Cancer
06/27
06/28
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Recruiting
1/2
150
US, RoW
JIN-A02
J Ints Bio
EGFR Mutant Advanced Non-small Cell Lung Cancer
07/24
11/25
KEYNOTE-C98, NCT05405595: ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Recruiting
1/2
131
US, RoW
ADG126, Pembrolizumab (KEYTRUDA®)
Adagene Inc, Merck Sharp & Dohme LLC
Advanced/Metastatic Solid Tumors
03/25
09/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Recruiting
1
400
Europe, US, RoW
KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib
Pierre Fabre Medicament
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
12/24
12/25
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
NCT04476862: Cerliponase Alfa Observational Study in the US

Active, not recruiting
N/A
35
US
Cerliponase Alfa, Brineura, Administration Kit
BioMarin Pharmaceutical
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
08/30
08/30

Download Options